ArticleLeukemia2006
Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations.
Article in Leukemia, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 66 citations in OpenAlex.
- Germline variants in IKZF1, ARID5B, and CEBPE as risk factors for adult-onset acute lymphoblastic leukemia: an analysis from the GMALL study group.Haematologica · 2014Trial
- Trial
- Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.Leukemia · 2024Article
- Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia.Haematologica · 2024Article
- Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment.Scientific reports · 2023Article
- The KMT2A recombinome of acute leukemias in 2023.Leukemia · 2023Article
- Rapid detection of myeloid neoplasm fusions using single-molecule long-read sequencing.PLOS global public health · 2023Article
- Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.British journal of cancer · 2022Article
- Circulating Tumor DNA in Pediatric Cancer.Frontiers in molecular biosciences · 2022Review
- KMT2A-ARHGEF12, a therapy related fusion with poor prognosis.Molecular biology reports · 2021Review
- Clinical Implications of Minimal Residual Disease Detection in Infants WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- The role of EVI1 gene quantification in AML patients with 11q23/MLL rearrangement after allogeneic hematopoietic stem cell transplantation.Bone marrow transplantation · 2021Article
- The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.International journal of molecular sciences · 2019Review
- Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances.Frontiers in oncology · 2019Review
- The MLL recombinome of acute leukemias in 2017.Leukemia · 2018Article
- Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date.Patient related outcome measures · 2018Review
- Loss-of-function but not dominant-negative intragenicHaematologica · 2017Article
- Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR.Molecular diagnosis & therapy · 2015Article
- Molecular characterization and clinical impact of t(11;15)(q23;q14-15) MLL-CASC5 rearrangement.Haematologica · 2014Article
- The MLL recombinome of acute leukemias in 2013.Leukemia · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An estimated 10% of acute leukemias carry mixed-lineage leukemia (MLL) fusion genes. Approximately 50 different fusion partners of the MLL gene have already been molecularly identified. These leukemias are commonly regarded as high-risk cases and are treated accordingly with intensified therapy regimens, including hematopoietic stem cell transplantation. However, a subset of patients may achieve long-term remissions with conventional therapy. Monitoring minimal residual disease (MRD) is undoubtedly of great value in clinical decision making, also in the pre- and post-transplant setting. Here, we describe a novel method for detecting MRD in leukemias with MLL aberrations. The method is based on monitoring patient-specific chromosomal breakpoint DNA sequences. This has several advantages over other methods that are based either on detecting specific RNA molecules of MLL fusion genes or on surrogate markers. An accurate and absolute quantification of the MRD level is possible. No reference to housekeeping genes is necessary and the target structure is much more stable than any mRNA fusion transcript.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.